Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Richard Pratley MD

Richard E. Pratley MD

Senior Investigator and Diabetes Program Lead, AdventHealth Translational Research Institute, Orlando, Florida; Medical Director, AdventHealth Diabetes Institute, Orlando, Florida; Adjunct Professor of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland

Dr. Richard Pratley, an internationally recognized expert in diabetes, is Senior Investigator and Diabetes Program Lead at the AdventHealth Translational Research Institute and Medical Director of the AdventHealth Diabetes Institute in Orlando, as well as Adjunct Professor of Medicine, Johns Hopkins University School of Medicine.

Dr. Pratley is a principal investigator for both NIH- and pharmaceutical company–sponsored trials in diabetes and obesity. His current research interests include the prevention of diabetes, improving the care of older individuals with diabetes, developing new drugs to treat and prevent diabetes and its complications, understanding the role of the fat cell in increasing the risk for diabetes and heart disease, and investigating extracellular vesicles in inter-cellular and inter-organ cross-talk. He presents his research regularly at national and international meetings and has written over 400 peer-reviewed articles. He is a member of the American Diabetes Association and the European Association for the Study of Diabetes. He has served on the editorial boards of a number of high-impact journals, including Diabetes Care, The Lancet Diabetes &Endocrinology, The Journal of Clinical Endocrinology and Metabolism, and the Journal of Diabetes and Its Complications.

Disclosures

  • Speaker fees: Eli Lilly; Novo Nordisk
  • Consulting fees: AbbVie; AstraZeneca; Bayer AG; Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim; Corcept Therapeutics; Eli Lilly; Endogenex; Gasherbrum Bio; Genprex; Getz Pharma; Hanmi Pharmaceutical Co; Intas Pharmaceuticals; Lexicon Pharmaceuticals; Lilly USA; Novo Nordisk; Pfizer; Regeneron; Rivus Pharmaceuticals, Scholar Rock; Sun Pharmaceutical Industries
  • Grants: Biomea Fusion; Carmot Therapeutics; Dompé; Endogenex; Fractyl Health; Eli Lilly; Novo Nordisk; Sanofi
  • Stock options: Altanine, Inc
  •  

Recent Contributions to PracticeUpdate:

  1. 2021 Top Story in Diabetes: Tirzepatide vs Semaglutide in Patients With Type 2 Diabetes
  2. Cardiovascular Outcomes With a Novel GLP-1 Receptor Agonist Efpeglenatide in Type 2 DM
  3. Effects of Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes
  4. Diabetes Risk Among Older Adults With Prediabetes
  5. Intensive Glucose Lowering in Older Patients With Diabetes
  6. Effect of Bimagrumab on Body Fat Mass in Type 2 Diabetes and Obesity
  7. Impact of CGM Among Adults With T1D on Insulin Pump Therapy
  8. 2020 Top Stories in Diabetes: Most Read COVID-19 and Diabetes Articles on PracticeUpdate
  9. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age
  10. 2019 Top Stories in Diabetes: Oral Semaglutide for the Treatment of Type 2 Diabetes

Most Read This Week

Recently Updated